PMID- 18509183
OWN - NLM
STAT- MEDLINE
DCOM- 20080625
LR  - 20220318
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 26
IP  - 16
DP  - 2008 Jun 1
TI  - High expression of macrophage colony-stimulating factor in peritumoral liver 
      tissue is associated with poor survival after curative resection of 
      hepatocellular carcinoma.
PG  - 2707-16
LID - 10.1200/JCO.2007.15.6521 [doi]
AB  - PURPOSE: To investigate prognostic values of the intratumoral and peritumoral 
      expression of macrophage colony-stimulating factors (M-CSF) in hepatocellular 
      carcinoma (HCC) patients after curative resection. PATIENTS AND METHODS: 
      Expression of M-CSF and density of macrophages (M Phi) were assessed by 
      immunohistochemistry in tissue microarrays containing paired tumor and 
      peritumoral liver tissue from 105 patients who had undergone hepatectomy for 
      histologically proven HCC. Prognostic value of these and other clinicopathologic 
      factors was evaluated. RESULTS: Neither intratumoral M-CSF nor M Phi density was 
      associated with overall survival (OS) or disease-free survival (DFS). High 
      peritumoral M-CSF and M Phi density, which correlated with large tumor size, 
      presence of intrahepatic metastasis, and high TNM stage, were independent 
      prognostic factors for both OS (P = .001 and P < .001, respectively) and DFS (P = 
      .001 and P = .003, respectively) and affected incidence of early recurrence. In a 
      small HCC subset, peritumoral M-CSF was also correlated with both OS and DFS (P = 
      .038 and P = .001, respectively). The combination of peritumoral M-CSF and M Phi 
      had a better power to predict the patients' death and disease recurrence (P < 
      .001 for both). CONCLUSION: High peritumoral M-CSF and M Phi were associated with 
      HCC progression, disease recurrence, and poor survival after hepatectomy, 
      highlighting the importance of peritumoral tissue in the recurrence and 
      metastasis of HCC. M-CSF and M Phi may be targets of postoperative adjuvant 
      therapy.
FAU - Zhu, Xiao-Dong
AU  - Zhu XD
AD  - Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai 200032, 
      China.
FAU - Zhang, Ju-Bo
AU  - Zhang JB
FAU - Zhuang, Peng-Yuan
AU  - Zhuang PY
FAU - Zhu, Hong-Guang
AU  - Zhu HG
FAU - Zhang, Wei
AU  - Zhang W
FAU - Xiong, Yu-Quan
AU  - Xiong YQ
FAU - Wu, Wei-Zhong
AU  - Wu WZ
FAU - Wang, Lu
AU  - Wang L
FAU - Tang, Zhao-You
AU  - Tang ZY
FAU - Sun, Hui-Chuan
AU  - Sun HC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 81627-83-0 (Macrophage Colony-Stimulating Factor)
SB  - IM
EIN - J Clin Oncol. 2008 Jul 20;26(21):3659
EIN - J Clin Oncol. 2013 Aug 20;31(24):3049
MH  - Carcinoma, Hepatocellular/*metabolism/pathology/surgery
MH  - Disease-Free Survival
MH  - Hepatectomy
MH  - Humans
MH  - Immunohistochemistry
MH  - Liver Neoplasms/*metabolism/pathology/surgery
MH  - Macrophage Colony-Stimulating Factor/*metabolism
MH  - Microarray Analysis
MH  - Neoplasm Recurrence, Local
MH  - Neoplasm Staging
MH  - Prognosis
EDAT- 2008/05/30 09:00
MHDA- 2008/06/26 09:00
CRDT- 2008/05/30 09:00
PHST- 2008/05/30 09:00 [pubmed]
PHST- 2008/06/26 09:00 [medline]
PHST- 2008/05/30 09:00 [entrez]
AID - 26/16/2707 [pii]
AID - 10.1200/JCO.2007.15.6521 [doi]
PST - ppublish
SO  - J Clin Oncol. 2008 Jun 1;26(16):2707-16. doi: 10.1200/JCO.2007.15.6521.